Gilman Hill Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gilman Hill Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.45M	Buy	7,139 +939	+15%	+$639K	0.61%	71
2026 Q1	$4.79M	Buy	6,200 +229	+4%	+$175K	0.72%	59
2025 Q4	$4.61M	Buy	5,971 +450	+8%	+$306K	0.73%	66
2025 Q3	$3.1M	Buy	5,521 +106	+2%	+$59.9K	0.49%	78
2025 Q2	$2.84M	Buy	5,415 +112	+2%	+$62.5K	0.46%	75
2025 Q1	$3.36M	Buy	5,303 +100	+2%	+$68.8K	0.58%	68
2024 Q4	$3.71M	Buy	5,203 +58	+1%	+$48.7K	0.65%	60
2024 Q3	$5.41M	Buy	5,145 +22	+0.4%	+$24.5K	0.9%	40
2024 Q2	$5.38M	Buy	5,123 +231	+5%	+$224K	0.97%	34
2024 Q1	$4.71M	Sell	4,892 -15	-0.3%	-$14.3K	0.84%	38
2023 Q4	$4.31M	Sell	4,907 -187	-4%	-$154K	0.8%	45
2023 Q3	$4.19M	Sell	5,094 -927	-15%	-$729K	0.82%	44
2023 Q2	$4.33M	Buy	6,021 +285	+5%	+$220K	0.81%	45
2023 Q1	$4.71M	Buy	5,736 +187	+3%	+$141K	0.96%	38
2022 Q4	$4M	Buy	5,549 +72	+1%	+$53.1K	0.82%	45
2022 Q3	$3.77M	Buy	5,477 +549	+11%	+$346K	0.88%	38
2022 Q2	$2.91M	Buy	4,928 +554	+13%	+$360K	0.63%	48
2022 Q1	$3.06M	Sell	4,374 -55	-1%	-$34.8K	0.7%	43
2021 Q4	$2.8M	Buy	4,429 +222	+5%	+$136K	0.62%	43
2021 Q3	$2.55M	Buy	4,207 +248	+6%	+$154K	0.65%	45
2021 Q2	$2.21M	Buy	3,959 +108	+3%	+$54.7K	0.57%	55
2021 Q1	$1.82M	Buy	+3,851	New	+$1.87M	0.5%	57
2019 Q2	–	Sell	-500	Closed	-$205K	–	192
2019 Q1	$205K	Buy	+500	New	+$206K	0.07%	172
2018 Q4	–	Sell	-525	Closed	-$212K	–	186
2018 Q3	$212K	Buy	+525	New	+$200K	0.08%	161

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gilman Hill Asset Management's REGN Position: Q2 2026 in Review

Gilman Hill Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, buying an estimated $639K and bringing the position to 7,139 shares worth $4.45M. The position accounts for 0.61% of the portfolio, ranked #71.

Gilman Hill Asset Management first reported a position in REGN in Q3 2018 and has held it in 24 quarters since. The position peaked at $5.41M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Gilman Hill Asset Management held 7,139 shares of Regeneron Pharmaceuticals worth $4.45M as of Q2 2026.
Gilman Hill Asset Management bought 939 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $639K.
Regeneron Pharmaceuticals made up 0.61% of Gilman Hill Asset Management's portfolio in Q2 2026, its #71 holding.
Gilman Hill Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 24 quarters since.
Gilman Hill Asset Management's Regeneron Pharmaceuticals position peaked at $5.41M in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Gilman Hill Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.